Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market. The market is huge — a potential $150 billion a year by the end of the ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have all become blockbuster drugs, and their momentum ... updates around its three weight loss candidates: AZD5004, AZD6234 ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals ... It consists of the company's weight loss drugs: Mounjaro, approved for type 2 diabetes but also prescribed off-label for weight ...

Shares of Amgen (NASDAQ:AMGN) rebounded Wednesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. One analyst said the ...